September 23, 2008
Gemin X Announces Key U.S. Patent Issued for Obatoclax
Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced that the United States Patent & Trademark Office issued to Gemin X a patent protecting the composition of matter of obatoclax through 2025 - U.S. Patent No. 7,425,553. One of Gemin X's lead pipeline programs, obatoclax is an oncology treatment based on programmed cell death, or apoptosis, and has the potential to be a first-in-class pan Bcl-2 inhibitor. Obatoclax is currently in Phase 2 clinical trials for the treatment of elderly acute myeloid leukemia and the treatment of small cell lung cancer.
"This key patent is core to our overall IP strategy and provides important protection for our obatoclax program," said Glenn J. Gormley, M.D., Ph.D., President and CEO of Gemin X. "We are excited about the potential of obatoclax - used as a single agent or in combination with other therapies - to treat a range of cancers and we look forward to advancing this program."About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X is developing first-in-class cancer therapeutics based on reinitiating the natural process of programmed cell death, or apoptosis, and triggering metabolic inhibitors in cancerous cells. Gemin X currently has three clinical development programs underway, ranging from Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, to preclinical studies for its Telomere Capping program. Initial treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including elderly acute myeloid leukemia (AML), mantle cell lymphoma (MCL), melanoma, glioblastoma and small cell lung cancer (SCLC). Founded in 1998, Gemin X is privately held with drug development and executive headquarters in Malvern, Pennsylvania and drug discovery operations in Montreal, Canada. For more information, visit www.geminx.com.